Targeting IL-17 in psoriasis: From cutaneous immunobiology to clinical application

Clinical Immunology

Volumn 146, Issue 2, 2013, Pages 131-139

  Ariza, Maria Eugenia ^a   Williams, Marshall V ^a   Wong, Henry K ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

IL 17; ; Inflammation; Psoriasis; ; T cells; ; TH17; ; Therapy;

Indexed keywords

BRODALUMAB; CD8 ANTIGEN; INTERLEUKIN 17; IXEKIZUMAB; PLACEBO;

ADAPTIVE IMMUNITY; CD8+ T LYMPHOCYTE; DENDRITIC CELL; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HOMEOSTASIS; HUMAN; IMMUNOBIOLOGY; INNATE IMMUNITY; NEUTROPENIA; PRIORITY JOURNAL; PSORIASIS; REVIEW; TH17 CELL; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; INTERLEUKIN-17; MOLECULAR TARGETED THERAPY; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 84872348231     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.12.004     Document Type: Review

References (98)

1. Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu. Rev. Pathol. 2012, 7:385-422.
2. Gudjonsson J.E., Elder J.T. Psoriasis: epidemiology. Clin. Dermatol. 2007, 25:535-546.
3. Mease P.J. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann. Rheum. Dis. 2011, 70(Suppl. 1):i77-i84.
4. B.H. Kaffenberger, H.K. Wong, W. Jarjour, L.A. Andritsos, Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation, J. Am. Acad. Dermatol. (in press), http://dx.doi.org/10.1016/j.jaad.2012.08.021.
5. Al-Daraji W.I., Grant K.R., Ryan K., Saxton A., Reynolds N.J. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J. Invest. Dermatol. 2002, 118:779-788.
6. Bowcock A.M., Krueger J.G. Getting under the skin: the immunogenetics of psoriasis. Nat. Rev. Immunol. 2005, 5:699-711.
7. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009, 361:496-509.
8. Waite J.C., Skokos D. Th17 response and inflammatory autoimmune diseases. Int. J. Inflam. 2012, 2012:819467.
9. Nograles K.E., Brasington R.D., Bowcock A.M. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat. Clin. Pract. Rheumatol. 2009, 5:83-91.
10. Gudjonsson J.E., Thorarinsson A.M., Sigurgeirsson B., Kristinsson K.G., Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br. J. Dermatol. 2003, 149:530-534.
11. Valdimarsson H., Thorleifsdottir R.H., Sigurdardottir S.L., Gudjonsson J.E., Johnston A. Psoriasis-as an autoimmune disease caused by molecular mimicry. Trends Immunol. 2009, 30:494-501.
12. Nahary L., Tamarkin A., Kayam N., Sela S., Fry L., Baker B., Powles A., Rogers S., Benhar I. An investigation of antistreptococcal antibody responses in guttate psoriasis. Arch. Dermatol. Res. 2008, 300:441-449.
13. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., Cao W., Su B., Nestle F.O., Zal T., Mellman I., Schroder J.M., Liu Y.J., Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
14. Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., Homey B., Barrat F.J., Zal T., Gilliet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 2009, 206:1983-1994.
15. Ellinghaus E., Ellinghaus D., Stuart P.E., Nair R.P., Debrus S., Raelson J.V., Belouchi M., Fournier H., Reinhard C., Ding J., Li Y., Tejasvi T., Gudjonsson J., Stoll S.W., Voorhees J.J., Lambert S., Weidinger S., Eberlein B., Kunz M., Rahman P., Gladman D.D., Gieger C., Wichmann H.E., Karlsen T.H., Mayr G., Albrecht M., Kabelitz D., Mrowietz U., Abecasis G.R., Elder J.T., Schreiber S., Weichenthal M., Franke A. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 2010, 42:991-995.
16. Menssen A., Trommler P., Vollmer S., Schendel D., Albert E., Gurtler L., Riethmuller G., Prinz J.C. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J. Immunol. 1995, 155:4078-4083.
17. Prinz J.C., Vollmer S., Boehncke W.H., Menssen A., Laisney I., Trommler P. Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur. J. Immunol. 1999, 29:3360-3368.
18. Vollmer S., Menssen A., Prinz J.C. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J. Invest. Dermatol. 2001, 117:1296-1301.
19. Vollmer S., Menssen A., Trommler P., Schendel D., Prinz J.C. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur. J. Immunol. 1994, 24:2377-2382.
20. Ortega C., Fernandez A.S., Carrillo J.M., Romero P., Molina I.J., Moreno J.C., Santamaria M. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 2009, 86:435-443.
21. Res P.C., Piskin G., de Boer O.J., van der Loos C.M., Teeling P., Bos J.D., Teunissen M.B. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010, 5:e14108.
22. Capon F., Burden A.D., Trembath R.C., Barker J.N. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J. Invest. Dermatol. 2012, 132:915-922.
23. Lai O.Y., Chen H., Michaud H.A., Hayashi G., Kuebler P.J., Hultman G.K., Ariza M.E., Williams M.V., Batista M.D., Nixon D.F., Foerster J., Bowcock A.M., Liao W. Protective effect of human endogenous retrovirus K dUTPase variants on psoriasis susceptibility. J. Invest. Dermatol. 2012, 132:1833-1840.
24. Ariza M.E., Williams M.V. A human endogenous retrovirus K dUTPase triggers a TH1, TH17 cytokine response: does it have a role in psoriasis?. J. Invest. Dermatol. 2011, 131:2419-2427.
25. Nickoloff B.J. Cracking the cytokine code in psoriasis. Nat. Med. 2007, 13:242-244.
26. Zaba L.C., Krueger J.G., Lowes M.A. Resident and "inflammatory" dendritic cells in human skin. J. Invest. Dermatol. 2009, 129:302-308.
27. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 2010, 130:1373-1383.
28. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., Dhodapkar M., Krueger J.G. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 2004, 199:125-130.
29. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 2009, 129:1339-1350.
30. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K.P., Vega F., To W., Wagner J., O'Farrell A.M., McClanahan T., Zurawski S., Hannum C., Gorman D., Rennick D.M., Kastelein R.A., de Waal Malefyt R., Moore K.W. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 2002, 168:5699-5708.
31. Hue S., Ahern P., Buonocore S., Kullberg M.C., Cua D.J., McKenzie B.S., Powrie F., Maloy K.J. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 2006, 203:2473-2483.
32. Ahern P.P., Schiering C., Buonocore S., McGeachy M.J., Cua D.J., Maloy K.J., Powrie F. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010, 33:279-288.
33. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., Schluns K., Tian Q., Watowich S.S., Jetten A.M., Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
34. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007, 8:942-949.
35. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., Basham B., Smith K., Chen T., Morel F., Lecron J.C., Kastelein R.A., Cua D.J., McClanahan T.K., Bowman E.P., de Waal Malefyt R. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 2007, 8:950-957.
36. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., McClanahan T.K., O'Shea J.J., Cua D.J. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 2009, 10:314-324.
37. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
38. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
39. Roark C.L., Simonian P.L., Fontenot A.P., Born W.K., O'Brien R.L. gammadelta T cells: an important source of IL-17. Curr. Opin. Immunol. 2008, 20:353-357.
40. Rachitskaya A.V., Hansen A.M., Horai R., Li Z., Villasmil R., Luger D., Nussenblatt R.B., Caspi R.R. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J. Immunol. 2008, 180:5167-5171.
41. Cai Y., Shen X., Ding C., Qi C., Li K., Li X., Jala V.R., Zhang H.G., Wang T., Zheng J., Yan J. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011, 35:596-610.
42. Pappu R., Ramirez-Carrozzi V., Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 2011, 134:8-16.
43. Nistala K., Wedderburn L.R. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford) 2009, 48:602-606.
44. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez-Farinas M., Fuentes-Duculan J., Novitskaya I., Khatcherian A., Bluth M.J., Lowes M.A., Krueger J.G. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 2007, 204:3183-3194.
45. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Abello M.V., Novitskaya I., Pierson K.C., Gonzalez J., Krueger J.G., Lowes M.A. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J. Invest. Dermatol. 2009, 129:79-88.
46. Rauen T., Hedrich C.M., Juang Y.T., Tenbrock K., Tsokos G.C. cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J. Biol. Chem. 2011, 286:43437-43446.
47. Juang Y.T., Rauen T., Wang Y., Ichinose K., Benedyk K., Tenbrock K., Tsokos G.C. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. J. Biol. Chem. 2011, 286:1795-1801.
48. Solomou E.E., Juang Y.T., Gourley M.F., Kammer G.M., Tsokos G.C. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 2001, 166:4216-4222.
49. Kyttaris V.C., Wang Y., Juang Y.T., Weinstein A., Tsokos G.C. CAMP response element modulator a expression in patients with systemic lupus erythematosus. Lupus 2006, 15:840-844.
50. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
51. Krueger J.G., Fretzin S., Suarez-Farinas M., Haslett P.A., Phipps K.M., Cameron G.S., McColm J., Katcherian A., Cueto I., White T., Banerjee S., Hoffman R.W. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012, 130:145-154.
52. Wolk K., Witte E., Witte K., Warszawska K., Sabat R. Biology of interleukin-22. Semin. Immunopathol. 2010, 32:17-31.
53. Wolk K., Haugen H.S., Xu W., Witte E., Waggie K., Anderson M., Vom Baur E., Witte K., Warszawska K., Philipp S., Johnson-Leger C., Volk H.D., Sterry W., Sabat R. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J. Mol. Med. (Berl) 2009, 87:523-536.
54. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 2009, 10:864-871.
55. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 2009, 10:857-863.
56. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 2005, 174:3695-3702.
57. Wolk K., Witte E., Wallace E., Docke W.D., Kunz S., Asadullah K., Volk H.D., Sterry W., Sabat R. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 2006, 36:1309-1323.
58. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
59. Guttman-Yassky E., Lowes M.A., Fuentes-Duculan J., Zaba L.C., Cardinale I., Nograles K.E., Khatcherian A., Novitskaya I., Carucci J.A., Bergman R., Krueger J.G. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J. Immunol. 2008, 181:7420-7427.
60. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
61. Chu C.C., Di Meglio P., Nestle F.O. Harnessing dendritic cells in inflammatory skin diseases. Semin. Immunol. 2011, 23:28-41.
62. Coquerelle C., Moser M. DC subsets in positive and negative regulation of immunity. Immunol. Rev. 2010, 234:317-334.
63. McGeachy M.J., Cua D.J. Th17 cell differentiation: the long and winding road. Immunity 2008, 28:445-453.
64. Ivanov I.I., Zhou L., Littman D.R. Transcriptional regulation of Th17 cell differentiation. Semin. Immunol. 2007, 19:409-417.
65. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., Burg G., Liu Y.J., Gilliet M. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 2005, 202:135-143.
66. Nestle F.O., Nickoloff B.J. Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin. Dermatol. Clin. 1994, 12:271-282.
67. Austin L.M., Ozawa M., Kikuchi T., Walters I.B., Krueger J.G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 1999, 113:752-759.
68. Nestle F.O., Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 2004, 123:xiv-xv.
69. Lowes M.A., Chamian F., Abello M.V., Fuentes-Duculan J., Lin S.L., Nussbaum R., Novitskaya I., Carbonaro H., Cardinale I., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Wittkowski K.M., Papp K., Garovoy M., Dummer W., Steinman R.M., Krueger J.G. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. U. S. A. 2005, 102:19057-19062.
70. Wang F., Lee E., Lowes M.A., Haider A.S., Fuentes-Duculan J., Abello M.V., Chamian F., Cardinale I., Krueger J.G. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J. Invest. Dermatol. 2006, 126:1590-1599.
71. Chong B.F., Wong H.K. Immunobiologics in the treatment of psoriasis. Clin. Immunol. 2007, 123:129-138.
72. Okamoto H., Momohara S. Interleukin-12/23 monoclonal antibody for psoriasis. N. Engl. J. Med. 2007, 356:2003. (author reply 2003).
73. Krueger G., Ellis C.N. Psoriasis-recent advances in understanding its pathogenesis and treatment. J. Am. Acad. Dermatol. 2005, 53:S94-S100.
74. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Johnson-Huang L.M., Nograles K.E., White T.R., Pierson K.C., Lentini T., Suarez-Farinas M., Lowes M.A., Krueger J.G. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J. Allergy Clin. Immunol. 2010, 125:1261-1268. (e9).
75. Papp K.A., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., Aras G., Li J., Russell C.B., Thompson E.H., Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 2012, 366:1181-1189.
76. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., Braun D., Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 2012, 366:1190-9.
77. Papp K.A., Reid C., Foley P., Sinclair R., Salinger D.H., Williams G., Dong H., Krueger J.G., Russell C.B., Martin D.A. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase i, randomized, placebo-controlled trial. J. Invest. Dermatol. 2012, 132:2466-2469.
78. von Vietinghoff S., Ley K. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J. Immunol. 2009, 183:865-873.
79. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., Gudjonsson J.E., Li Y., Tejasvi T., Feng B.J., Ruether A., Schreiber S., Weichenthal M., Gladman D., Rahman P., Schrodi S.J., Prahalad S., Guthery S.L., Fischer J., Liao W., Kwok P.Y., Menter A., Lathrop G.M., Wise C.A., Begovich A.B., Voorhees J.J., Elder J.T., Krueger G.G., Bowcock A.M., Abecasis G.R. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 2009, 41:199-204.
80. Elder J.T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 2009, 10:201-209.
81. Nair R.P., Henseler T., Jenisch S., Stuart P., Bichakjian C.K., Lenk W., Westphal E., Guo S.W., Christophers E., Voorhees J.J., Elder J.T. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum. Mol. Genet. 1997, 6:1349-1356.
82. Helms C., Cao L., Krueger J.G., Wijsman E.M., Chamian F., Gordon D., Heffernan M., Daw J.A., Robarge J., Ott J., Kwok P.Y., Menter A., Bowcock A.M. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. 2003, 35:349-356.
83. Foerster J., Nolte I., Schweiger S., Ehlert C., Bruinenberg M., Spaar K., van der Steege G., Mulder M., Kalscheuer V., Moser B., Kijas Z., Seeman P., Stander M., Sterry W., te Meerman G. Evaluation of the IRF-2 gene as a candidate for PSORS3. J. Invest. Dermatol. 2004, 122:61-64.
84. Zhang X.J., Huang W., Yang S., Sun L.D., Zhang F.Y., Zhu Q.X., Zhang F.R., Zhang C., Du W.H., Pu X.M., Li H., Xiao F.L., Wang Z.X., Cui Y., Hao F., Zheng J., Yang X.Q., Cheng H., He C.D., Liu X.M., Xu L.M., Zheng H.F., Zhang S.M., Zhang J.Z., Wang H.Y., Cheng Y.L., Ji B.H., Fang Q.Y., Li Y.Z., Zhou F.S., Han J.W., Quan C., Chen B., Liu J.L., Lin D., Fan L., Zhang A.P., Liu S.X., Yang C.J., Wang P.G., Zhou W.M., Lin G.S., Wu W.D., Fan X., Gao M., Yang B.Q., Lu W.S., Zhang Z., Zhu K.J., Shen S.K., Li M., Zhang X.Y., Cao T.T., Ren W., Zhang X., He J., Tang X.F., Lu S., Yang J.Q., Zhang L., Wang D.N., Yuan F., Yin X.Y., Huang H.J., Wang H.F., Lin X.Y., Liu J.J. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat. Genet. 2009, 41:205-210.
85. de Cid R., Riveira-Munoz E., Zeeuwen P.L., Robarge J., Liao W., Dannhauser E.N., Giardina E., Stuart P.E., Nair R., Helms C., Escaramis G., Ballana E., Martin-Ezquerra G., den Heijer M., Kamsteeg M., Joosten I., Eichler E.E., Lazaro C., Pujol R.M., Armengol L., Abecasis G., Elder J.T., Novelli G., Armour J.A., Kwok P.Y., Bowcock A., Schalkwijk J., Estivill X. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat. Genet. 2009, 41:211-215.
86. Enlund F., Samuelsson L., Enerback C., Inerot A., Wahlstrom J., Yhr M., Torinsson A., Riley J., Swanbeck G., Martinsson T. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur. J. Hum. Genet. 1999, 7:783-790.
87. Vasilopoulos Y., Walters K., Cork M.J., Duff G.W., Sagoo G.S., Tazi-Ahnini R. Association analysis of the skin barrier gene cystatin A at the PSORS5 locus in psoriatic patients: evidence for interaction between PSORS1 and PSORS5. Eur. J. Hum. Genet. 2008, 16:1002-1009.
88. Huffmeier U., Lascorz J., Becker T., Schurmeier-Horst F., Magener A., Ekici A.B., Endele S., Thiel C.T., Thoma-Uszynski S., Mossner R., Reich K., Kurrat W., Wienker T.F., Traupe H., Reis A. Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. J. Med. Genet. 2009, 46:736-744.
89. Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L., Timms K., Gutin A., Abkevic V., Burden A.D., Lanchbury J., Barker J.N., Trembath R.C., Nestle F.O. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 2007, 122:201-206.
90. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., Matsunami N., Ardlie K.G., Civello D., Catanese J.J., Leong D.U., Panko J.M., McAllister L.B., Hansen C.B., Papenfuss J., Prescott S.M., White T.J., Leppert M.F., Krueger G.G., Begovich A.B. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 2007, 80:273-290.
91. Zhang X.J., He P.P., Wang Z.X., Zhang J., Li Y.B., Wang H.Y., Wei S.C., Chen S.Y., Xu S.J., Jin L., Yang S., Huang W. Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. J. Invest. Dermatol. 2002, 119:1361-1366.
92. Asumalahti K., Laitinen T., Lahermo P., Suomela S., Itkonen-Vatjus R., Jansen C., Karvonen J., Karvonen S.L., Reunala T., Snellman E., Uurasmaa T., Saarialho-Kere U., Kere J. Psoriasis susceptibility locus on 18p revealed by genome scan in Finnish families not associated with PSORS1. J. Invest. Dermatol. 2003, 121:735-740.
93. Hofstetter H., Gold R., Hartung H.P. Th17 cells in MS and experimental autoimmune encephalomyelitis. Int. MS J. 2009, 16:12-18.
94. van den Berg W.B., Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:549-553.
95. Crispin J.C., Liossis S.N., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.T., Tsokos G.C. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 2010, 16:47-57.
96. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., Bowman E.P., Krueger J.G. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 2008, 128:1207-1211.
97. Sarra M., Pallone F., Macdonald T.T., Monteleone G. IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 2010, 16:1808-13.
98. Emamaullee J.A., Davis J., Merani S., Toso C., Elliott J.F., Thiesen A., Shapiro A.M. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009, 58:1302-1311.